Table 2.

Patient characteristics by PFS and overall survival OS

		n	2-Year PFS (%; 95% CI)	P value	2-Year OS (%; 95% CI)	P value
	Overall	54	9 (1–17)		19 (7–31)
Age	Age 17 years or younger	29	14 (2–26)	0.1	30 (12–48)	0.07
	Age 18 years or older	25	4 (0–12)		5 (0–15)
Gender	Female	26	4 (0–12)	0.1	9 (0–21)	0.1
	Male	28	14 (0–28)		29 (9–49)
Tumor location	Thoracic	31	3 (0–9)	0.04	15 (1–29)	0.1
	Head/neck	19	16 (0–32)		27 (2–52)
	Other locations	4	25 (0–68)		25 (0–68)
Tumor histology	Carcinoma with squamous differentiation	21	14 (0–30)	0.4	33 (9–57)	0.2
	Carcinoma without squamous differentiation	23	4 (0–12)		6 (0–18)
	Other histology	9	11 (0–33)		22 (0–49)
NUT translocation	BRD4-NUT	38	8 (0–12)	0.1	12 (0–24)	0.4
	BRD3-NUT	3	0		33 (0–86)
	NUT-variant	12	17 (0–39)		33 (6–60)
Metastases	No metastases	21	19 (1–37)	0.04	25 (3–37)	0.1
	Metastases	32	3 (0–9)		16 (2–26)
Lymph node	No involvement	29	10 (0–22)	0.3	20 (2–38)	0.3
involvement	Involvement	25	8 (0–18)		18 (2–34)
Extent of surgical resection	Less than gross total	10	10 (0–30)	0.01	44 (7–81)	0.03
	Complete	5	60 (17–100)		80 (45–100)
	Less than gross total or no surgical resection	49	4 (0–10)	0.001	12 (0–24)	0.002
	Complete	5	60 (17–100)		80 (45–100)
Initial radiotherapy	No	27	0	<0.0001	5 (0–15)	0.0003
	Yes	26	19 (3–35)		35 (13–57)
Chemotherapy regimen	Platinum-based	33	9 (0–19)	0.6	22 (4–40)	0.3
	Other	20	10 (0–24)		15 (0–31)
	Anthracycline/alkylator-based	17	18 (0–36)	0.6	28 (4–40)	0.4
	Other	36	6 (0–14)		15 (1–29)